J. Dignam

发表

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials

J. Bryant, N. Wolmark, B. Fisher, 2004, The Lancet.

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.

Norman Wolmark, James J Dignam, Soonmyung Paik, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses

L. Collette, M. Sydes, M. Regan, 2019, JNCI cancer spectrum.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

P. Kantoff, L. Collette, M. Sydes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

B Fisher, J. Bryant, D. Wickerham, 1997, Journal of the National Cancer Institute.

The Use and Interpretation of Competing Risks Regression Models

J. Dignam, M. Kocherginsky, Qiang Zhang, 2012, Clinical Cancer Research.

Choice and interpretation of statistical tests used when competing risks are present.

J. Dignam, M. Kocherginsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design and Analysis of Oncology Clinical Trials

J. Bryant, J. Dignam, T. Karrison, 2006 .

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

James Dignam, Norman Wolmark, Mirsada Begovic, 1999, The Lancet.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

B Fisher, J Costantino, C. Redmond, 1996, Journal of the National Cancer Institute.

Hazard of Recurrence among Women after Primary Breast Cancer Treatment–A 10-Year Follow-up Using Data from SEER-Medicare

J. Dignam, 2013 .

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

Vanja Dukic, Norman Wolmark, V. Dukic, 2009, Breast Cancer Research and Treatment.

Benefits and costs of interventions to improve breast cancer outcomes in African American women.

Peter Muennig, Jennifer Cullen, James Dignam, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flexible modeling of the hazard rate and treatment effects in long-term survival studies

V. Dukic, J. Dignam, Y. Hagar, 2017, Statistical methods in medical research.

Modeling Long-term Outcomes and Treatment Effects After Androgen Deprivation Therapy for Prostate Cancer

V. Dukic, J. Dignam, Y. Hagar, 2015, 1509.01275.

Multiple imputation methods for nonparametric inference on cumulative incidence with missing cause of failure

J. Dignam, Junhee Han, Minjung Lee, 2014, Statistics in medicine.

Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

E. Mamounas, B. Fisher, J. Dignam, 2003, Journal of the National Cancer Institute.

Duration of adjuvant tamoxifen therapy.

J. Bryant, B. Fisher, J. Dignam, 2001, Journal of the National Cancer Institute. Monographs.

Coronary heart disease mortality and adjuvant tamoxifen therapy.

L. Kuller, J. Costantino, B. Fisher, 1997, Journal of the National Cancer Institute.

A nomogram for individualized estimation of survival among patients with brain metastasis.

Meihua Wang, M. Mehta, A. Sloan, 2012, Neuro-oncology.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

N. Wolmark, B. Fisher, E. Fisher, 2001, Journal of the National Cancer Institute.

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and

C. Redmond, J. Costantino, D. Wickerham, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

C. N. Coleman, P. Okunieff, W. Curran, 2013, Journal of the National Cancer Institute.

NCI-RTOG Translational-Program Strategic Guidelines for the Early Stage Development of Radiosensitizers

C. N. Coleman, P. Okunieff, W. Curran, 2012 .

An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population

O. Olopade, S. Gehlert, J. Dignam, 2017, Journal of Racial and Ethnic Health Disparities.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.

P. Brown, M. Gilbert, M. Mehta, 2018, International journal of radiation oncology, biology, physics.

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

G. Rosner, J. Griggs, G. Lyman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status.

W. Lawrence, J. Mandelblatt, J. Dignam, 2005, Journal of general internal medicine.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Christopher U. Jones, E. Sturgis, P. Harari, 2019, The Lancet.

Comparison of futility monitoring guidelines using completed phase III oncology trials

B. Freidlin, E. Korn, S. Mandrekar, 2017, Clinical trials.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

J. Cuzick, J. Bergh, R. Peto, 2022, The Lancet. Oncology.

Prevention of colorectal cancer and dietary management.

J. Dignam, D. Huo, N. Hou, 2013, Chinese clinical oncology.

Obesity and breast cancer prognosis: an expanding body of evidence.

E. Mamounas, J. Dignam, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Colorectal cancer model of health disparities: understanding mortality differences in minority populations.

O. Olopade, J. Dignam, B. Polite, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disparities in Breast Cancer: Narrowing the Gap.

J. Dignam, 2020, Journal of the National Cancer Institute.

Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group.

J. Dignam, 2010, Journal of the National Cancer Institute.

Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials.

B. Movsas, J. Dignam, D. Bruner, 2020, International journal of radiation oncology, biology, physics.

Competing Risks and Their Applications in Cancer Clinical Trials

D. Chen, J. Dignam, C. Hu, 2014 .

Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx

W. Curran, P. Hudgins, D. Shin, 2018, Cancer.

NRG Oncology RTOG 0415: A Randomized Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer

D. Low, H. Sandler, M. Amin, 2016 .

Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology

W. Curran, S. Yom, Q. Le, 2020, International Journal of Radiation Oncology*Biology*Physics.

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.

C. Perou, O. Olopade, J. Dignam, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor–Negative Breast Cancer

J. Dignam, G. Fleming, 2009 .

Differences in breast cancer prognosis among African‐American and Caucasian women

J. Dignam, 2000, CA: a cancer journal for clinicians.

OP-JNCI200154 349..350

J. Dignam, 2021 .

Predictors of Local Recurrence in a Population-Based Cohort of Women with Ductal Carcinoma In Situ Treated with Breast Conserving Surgery Alone

J. Dignam, I. Wapnir, 2011 .

Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24

T. Julian, J. Costantino, N. Wolmark, 2007 .

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

T. Julian, J. Costantino, N. Wolmark, 2011, Journal of the National Cancer Institute.

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update

G. Rosner, J. Griggs, G. Lyman, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

D. Sargent, N. Wolmark, R. Goldberg, 2011, Journal of the National Cancer Institute.

Breast tumor morphometry in relation to race reveals significant differences among Nigerians, African-Americans and Caucasian Americans

O. Olopade, J. Dignam, R. Nanda, 2004 .

Breast tumor morphometry in relation to race reveals significant differences among Nigerians, African-Americans and Caucasian Americans.

O. Olopade, J. Dignam, R. Nanda, 2004, Journal of Clinical Oncology.

"Intrinsic Gene Expression" subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry.

C. Perou, O. Olopade, J. Dignam, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project.

D. Wickerham, N. Wolmark, Roy E. Smith, 1999, Journal of the National Cancer Institute.

Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites.

O. Olopade, J. Dignam, B. Polite, 2005, The Medical clinics of North America.

Prognosis among African‐American women and white women with lymph node negative breast carcinoma

C. Redmond, B. Edwards, J. Costantino, 1997, Cancer.

Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers

O. Olopade, J. Dignam, R. Nanda, 2007, Breast Cancer Research and Treatment.

Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC)

D. Sargent, N. Wolmark, R. Goldberg, 2007 .

editorial Building Firm Foundations for Therapy Development

James J. Dignam, Theodore Karrison, J. Dignam, 2015 .

Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).

K. Aldape, D. Brachman, P. Brown, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re : Benzene and the Dose-Related Incidence of Hematologic Neoplasms in China

B. Fisher, J. Dignam, 1998 .

Methods for bounding the marginal survival distribution.

L. Weissfeld, J. Dignam, S. Anderson, 1995, Statistics in medicine.

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial

D. Low, H. Sandler, G. Swanson, 2019, JAMA oncology.

Occurrence of stroke with tamoxifen in NSABP B-24

B. Fisher, J. Dignam, 2000, The Lancet.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

K. Aldape, W. Curran, D. Brachman, 2014, The New England journal of medicine.

DCIS: evidence from radomized trials

S. Paik, J. Bryant, C. Geyer, 2003 .

Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup

S. Eggener, J. Dignam, S. Liauw, 2022, The Journal of urology.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

J. Costantino, C. Geyer, D. Wickerham, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial

A. Zietman, H. Sandler, R. Dess, 2019, International Journal of Radiation Oncology*Biology*Physics.

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

J. Bryant, N. Wolmark, B. Fisher, 2001, Journal of the National Cancer Institute.

Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

J. Costantino, D. Wickerham, N. Wolmark, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

C. N. Coleman, P. Okunieff, B. Freidlin, 2013 .

Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women.

J. Dignam, 2001, Journal of the National Cancer Institute. Monographs.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

D. Wickerham, N. Wolmark, E. Mamounas, 2001, Journal of the National Cancer Institute. Monographs.

Statistical Considerations in the Evaluation of Continuous Biomarkers

M. Polley, J. Dignam, 2021, The Journal of Nuclear Medicine.

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

H. Sandler, P. Tran, F. Feng, 2021, JAMA oncology.

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.

W. R. Lee, A. Kishan, A. Zietman, 2020, JAMA oncology.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

D. Grignon, A. Zietman, H. Sandler, 2017, The New England journal of medicine.

BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.

O. Olopade, Soma Das, M. Tretiakova, 2005, Cancer research.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17

J Costantino, S. Paik, B. Fisher, 1999, Cancer.

Predictors of competing mortality in advanced head and neck cancer.

R. Weichselbaum, E. Vokes, L. Mell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease volumes as a marker for patient response in malignant pleural mesothelioma.

S. Armato, J. Dignam, H. Kindler, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

M. Terris, A. Kishan, M. Cooperberg, 2019, JAMA oncology.

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

D. Berry, A. D'Amico, P. Kantoff, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.

N. Wolmark, M. O’connell, J. Dignam, 2006, Journal of the National Cancer Institute.

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

H. Sandler, M. Amin, T. Pisansky, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.

N. Wolmark, Roy E. Smith, E. Mamounas, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline comorbidities in a skin cancer prevention trial in Bangladesh

J. Baron, F. Jasmine, M. Kibriya, 2013, European journal of clinical investigation.

Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003).

K. Ang, M. Hammond, J. Cooper, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults.

O. Olopade, J. Dignam, C. Daugherty, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer

D. Wickerham, S. Anderson, J. Dignam, 2006, Breast Cancer Research and Treatment.

The role of cancer cooperative groups within the spectrum of cancer care.

J. Dignam, 2004, Cancer control : journal of the Moffitt Cancer Center.

Is patient travel distance associated with survival on phase II clinical trials in oncology?

E. Lamont, E. Vokes, J. Dignam, 2003, Journal of the National Cancer Institute.

Survival Analysis II

J. Dignam, 2020 .

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

D. Low, H. Sandler, M. Amin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of Cause-Specific Events in Competing Risks Survival Data

John Bryant, James J. Dignam, H.Sam Wieand, 2003, Advances in Survival Analysis.

Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.

N. Wolmark, E. Mamounas, B. Fisher, 2001, Seminars in oncology.

Race and the Prognostic Influence of p53 in Women with Breast Cancer

W. McCaskill-Stevens, S. Gehlert, J. Dignam, 2012, Annals of Surgical Oncology.

Family History of Pancreatic Cancer in a High-Risk Cancer Clinic: Implications for Risk Assessment

O. Olopade, J. Dignam, M. Hall, 2008, Journal of Genetic Counseling.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Cuzick, J. Bergh, R. Peto, 2021, The Lancet. Oncology.

Building firm foundations for therapy development.

J. Dignam, T. Karrison, 2015, Journal of the National Cancer Institute.

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

Stewart J Anderson, Norman Wolmark, James J Dignam, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MYC Is Amplified in BRCA1-Associated Breast Cancers

C. Perou, O. Olopade, B. Weber, 2004, Clinical Cancer Research.

Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy.

S. Paik, J. Bryant, J. Dignam, 2002, Methods in molecular biology.

The ongoing search for the sources of the breast cancer survival disparity.

J. Dignam, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations.

J. Dignam, Chen Hu, 2019, JCO precision oncology.

Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time

Milica Medved, Walter M Stadler, James Dignam, 2004, Journal of magnetic resonance imaging : JMRI.

Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast Cancer.

Vanja Dukić, James Dignam, V. Dukic, 2007, Bayesian analysis.

Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.

W. Curran, Meihua Wang, M. Gilbert, 2015, Neuro-oncology.

Long-Term Suppression of Tumor Growth by TNF Requires a Stat1- and IFN Regulatory Factor 1-Dependent IFN-γ Pathway but Not IL-12 or IL-181

J. Dignam, T. Blankenstein, H. Schreiber, 2004, The Journal of Immunology.

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

Olufunmilayo I. Olopade, Mark W. Lingen, Everett E. Vokes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated phase II/III clinical trials in oncology: A case study

Meihua Wang, M. Mehta, J. Degroot, 2012, Clinical trials.

Tamoxifen Use , and Outcomes in Women With Estrogen Receptor – Positive Early-Stage Breast Cancer

E. Mamounas, B. Fisher, J. Dignam, 2003 .

Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features

D. Kerr, Shiyong Li, M. Ye, 2019, International journal of cancer.

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis

O. Olopade, C. Polanczyk, D. Finkelstein, 2018, Front. Oncol..

Comments on: Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Time-varying pattern of recurrence risk for Chinese breast cancer patients

J. Dignam, Vanja M. Dukic, 2009, Breast Cancer Research and Treatment.

A missing data approach to semi‐competing risks problems

Paul J Rathouz, James J Dignam, J. Dignam, 2007, Statistics in medicine.

Tamoxi fen , Radiat ion Therapy , or Both for Prevent ion of Ips i la tera l Breast Tumor Recurrence Af ter Lumpectomy in Women With Invas ive Breast Cancers of One Cent imeter or Less

S. Paik, J. Bryant, D. Wickerham, 2002 .

Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.

Reshma Jagsi, Steven J Chmura, Anthony L Zietman, 2017, International journal of radiation oncology, biology, physics.

Toward optimal screening strategies for older women

W. Lawrence, J. Mandelblatt, J. Dignam, 2005, Journal of General Internal Medicine.

Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.

Greg Yothers, Clifton D. Fuller, Mehee Choi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mammographic density and breast cancer after ductal carcinoma in situ.

James J Dignam, T. Julian, L. Habel, 2004, Journal of the National Cancer Institute.

A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation

J. Dignam, S. Mohile, D. Petrylak, 2007, Cancer.

Assessing treatment benefit with competing risks not affected by the randomized treatment

B. Freidlin, E. Korn, J. Dignam, 2015, Statistics in medicine.

Diffusing capacity predicts long-term survival after lung resection for cancer.

J. Dignam, J. Siddique, W. Vigneswaran, 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer.

H. Sandler, M. Lock, J. Purdy, 2015 .

Semiparametric Models for Cumulative Incidence Functions

James J Dignam, J. Bryant, J. Dignam, 2004, Biometrics.

Estimating breast cancer‐specific and other‐cause mortality in clinical trial and population‐based cancer registry cohorts

Angela Mariotto, Eric Feuer, James J Dignam, 2009, Cancer.

RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

Robert Jeraj, Maria Werner-Wasik, Deborah T Blumenthal, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.

Dezheng Huo, Olufunmilayo I Olopade, James J Dignam, 2013, Journal of the National Cancer Institute.

Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project.

B Fisher, J. Bryant, N. Wolmark, 1998, Controlled clinical trials.

Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.

D. Grignon, H. Sandler, H. Lepor, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contamination of individuals by radon daughters: a preliminary study.

J. Dignam, J. Stebbings, 1988, Archives of environmental health.

p53 as a Marker of Prognosis in African-American Women with Breast Cancer

W. McCaskill-Stevens, S. Gehlert, J. Dignam, 2010, Annals of Surgical Oncology.

Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance.

Walter J Curran, Richard Simon, J Jack Lee, 2012, International journal of radiation oncology, biology, physics.

Early viewing of noninferiority trials in progress.

J. Dignam, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Tissue Biomarker–Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02

R. Stoyanova, H. Sandler, K. Bae, 2014, Clinical Cancer Research.

Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers

O. Olopade, J. Dignam, A. Bradbury, 2008, Genetics in Medicine.

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma

Samuel G Armato, Zacariah E Labby, James J Dignam, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

D. Grignon, H. Sandler, H. Lepor, 2015, International journal of radiation oncology, biology, physics.

Personalized Medicine and Imaging A Tissue Biomarker – Based Model That Identi fi es Patients with a High Risk of Distant Metastasis and Differential Survival by Length of AndrogenDeprivation Therapy in RTOG Protocol 92-02

R. Stoyanova, H. Sandler, K. Bae, 2014 .

Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures?

J. Dignam, D. Bruner, S. Pugh, 2020, Quality of Life Research.

Detecting a Survival Benefit to Dose Escalation-Reply.

J. Michalski, J. Dignam, K. Winter, 2019, JAMA oncology.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma

S. Armato, J. Dignam, H. Kindler, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Title Duration of Androgen Deprivation in Locally Advanced Prostate Cancer : Long-Term

D. Grignon, H. Lepor, T. Pisansky, 2017 .

Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126)

H. Sandler, M. Lock, J. Purdy, 2014 .

A Multiresolution Hazard Model for Multicenter Survival Studies

Vanja Dukić, Xiao-Li Meng, Peter Bouman, 2007, Journal of the American Statistical Association.

Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation

Cécile Proust-Lima, Hélène Jacqmin-Gadda, James J Dignam, 2016, Statistical methods in medical research.

Some additional thoughts on time-varying treatment effects in breast cancer.

J. Dignam, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conditional survival for patients with colon cancer: An analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) trials C-03 through C-06.

N. Wolmark, M. O’connell, J. Dignam, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Population-based survival-cure analysis of ER-negative breast cancer

E. Feuer, Lan Huang, A. Mariotto, 2010, Breast Cancer Research and Treatment.

130 HAZARD OF PROSTATE CANCER-SPECIFIC MORTALITY OVER TIME FOLLOWING RADICAL PROSTATECTOMY

S. Shikanov, S. Eggener, J. Dignam, 2010 .

Tamoxifen for intraductal cancer

B. Fisher, J. Dignam, 1999, The Lancet.

Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.

Kecheng Zhang, J. Dignam, B. Miladinovic, 2023, European urology.

Joint modelling of longitudinal and multi‐state processes: application to clinical progressions in prostate cancer

Virginie Rondeau, Cécile Proust-Lima, Hélène Jacqmin-Gadda, 2015, Statistics in medicine.

Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group.

C. Redmond, B. Edwards, M. Forman, 1993, Journal of the National Cancer Institute.

Baseline comorbidities in a skin cancer prevention trial in Bangladesh

J. Baron, F. Jasmine, M. Kibriya, 2013, European journal of clinical investigation.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

K. Aldape, W. Curran, D. Brachman, 2014, The New England journal of medicine.

Integrated phase II/III clinical trials in oncology: A case study

Meihua Wang, M. Mehta, J. Degroot, 2012, Clinical trials.

Choice and interpretation of statistical tests used when competing risks are present.

J. Dignam, M. Kocherginsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Use and Interpretation of Competing Risks Regression Models

J. Dignam, M. Kocherginsky, Qiang Zhang, 2012, Clinical Cancer Research.

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

R. Gelber, A. Tutt, M. Piccart, 2023, The Lancet.

Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003).

K. Ang, M. Hammond, J. Cooper, 2010 .

A randomized trial of selenium and vitamin E for primary prevention of non-melanoma skin cancer: Trial results and experience from a low-resource setting.

Yunus, J. Baron, F. Jasmine, 2017 .

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Christopher U. Jones, E. Sturgis, P. Harari, 2019, The Lancet.

Early Stopping of Cancer Clinical Trials

J. Bryant, J. Dignam, H. Wieand, 2005 .

Multiple imputation methods for inference on cumulative incidence with missing cause of failure

Minjung Lee, Eric J Feuer, Kathleen A Cronin, 2011, Biometrical journal. Biometrische Zeitschrift.

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma

S. Armato, J. Dignam, H. Kindler, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.